Serum thrombospondin‐2 level changes with liver stiffness improvement in patients with type 2 diabetes
Authors' conclusion
Serum TSP2 level decreased with LS after dapagliflozin treatment, and was independent of improvements in BW, glycemic control and hepatic steatosis, further supporting the potential of serum TSP2 level as a novel hepatic fibrosis biomarker in type 2 diabetes.
Study context
- Population
- Patients with T2D; baseline mean HbA1c 8.9%, controlled attenuation parameter (CAP) 289 dB/m, liver stiffness (LS) 5.8 kPa
- Participants
- 60 patients
- Comparison
- Dapagliflozin 10 mg vs sitagliptin 100 mg daily
- Dapagliflozinn = 30
- Sitagliptinn = 30reference
- Primary endpoint
- Change in serum thrombospondin-2 (TSP2) level and its relation to change in liver stiffness (LS) on transient elastography
- Follow-up
- 24 weeks
Methodological detailsrandomized
- Randomized
Primary result
As reported in the abstract
Change in serum TSP2 from baseline
- Serum TSP2 decreased significantly from baseline with dapagliflozin
- p = .035
- Change in TSP2 positively correlated with change in LS after dapagliflozin
- r = .487, p = .006
Further findings
Body weight (BW), CAP and LS improvement after 24 weeks
- Significant improvement in BW with dapagliflozin, not sitagliptin
- P = 0.012
- Significant improvement in CAP with dapagliflozin, not sitagliptin
- P = 0.015
- Significant improvement in LS with dapagliflozin, not sitagliptin
- P = 0.011
- Similar HbA1c lowering in both groups
Original publication
Serum thrombospondin‐2 level changes with liver stiffness improvement in patients with type 2 diabetes. Clin Endocrinol (Oxf). Published 21 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →